Buy Biocon; Target Of Rs 495: Sharekhan
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 495 in its research report dated October 23, 2020.
Oct 27, 2020 / 04:02 PM IST
Sharekhan's research repor on Biocon
Q2FY2021 was a soft quarter for Biocon. Revenues from operations grew by 11% y-o-y to Rs 1,745 crore. Adjusted PAT rose by 10.3% y-o-y to Rs. 173.8 crore. Improving traction in existing biosimilars, likely pick up in Semglee, geographical expansion are the key growth drivers for Biologics segment. Biocon has retained its guidance for $1 billion in revenues from the biologics segment by FY2022. The generics business too is expected to grow at a healthy pace driven largely by formulations. Possible listing of Biocon Bilogics provides value unlocking opportunity.
We retain Buy recommendation on the stock with a revised PT of Rs. 495.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.